- Research Article
- 10.1016/j.clnesp.2026.103135
Serum creatinine-to-cystatin C ratio at dialysis initiation predicts all-cause mortality: A retrospective cohort study.
- Mar 20, 2026
- Clinical nutrition ESPEN
- Motoki Ambe + 6 more +6
Publications from 2021 to 2026
Showing 10 of 192 papers
Serum creatinine-to-cystatin C ratio at dialysis initiation predicts all-cause mortality: A retrospective cohort study.
A case of pulmonary hamartoma with extrapulmonary growth
症例は67歳,女性.新型コロナウイルス感染症の精査で施行したCTで右肺尖部に腫瘤を認めた.CTでは右肺尖部に31 mmの充実型腫瘤を認め,一部で胸壁浸潤が疑われた.PET-CTではSUVmax2.8の集積を認めた.悪性腫瘍を否定できないため診断治療目的に手術を施行した.術中所見としては,右肺尖部に胸腔内に突出する白色腫瘍を認めた.腫瘍の大部分は胸腔内に存在し,一部で上葉に連続していた.肺部分切除を施行し手術を終了した.病理学的に肺過誤腫と診断した.肺過誤腫の多くは末梢発生で肺実質内に存在するが,稀に胸腔内に突出するような進展形式をとる.肺外進展を来す腫瘍として肺過誤腫も鑑別疾患として考慮する必要がある.
Read moreA Device-Free Respiratory Gating Technique for Dynamic CT Using Time-Density Curve Analysis: A Technical Report With Clinical Applications
Respiratory motion remains a major challenge in thoracic and cardiac CT. Conventional respiratory gating techniques often rely on external monitoring devices or dedicated software, which may complicate workflow and limit clinical availability. We developed a simple, device-free respiratory gating technique based on time-density curve (TDC) analysis derived directly from routinely acquired dynamic CT data. By placing a region of interest (ROI) on the chest wall, attenuation changes over time were analyzed to generate an intrinsic surrogate respiratory waveform, enabling retrospective identification of respiratory phases without additional hardware. The novelty of this approach lies in its use of intrinsic image data to generate a surrogate respiratory waveform, thereby eliminating the complexity and synchronization uncertainty associated with external monitoring devices.The proposed workflow was implemented using standard dynamic CT protocols and applied to representative clinical applications, including lung tumor motion assessment for radiotherapy planning and free-breathing coronary CT angiography (FB-CCTA) in a patient unable to perform reliable breath-holding. This image-based approach provides a practical method for respiratory phase estimation and may expand the clinical applicability of dynamic CT imaging in situations where conventional respiratory control is impractical.
Read moreXpert MTB/RIF probe reactivity to non-tuberculosis mycobacteria cultured in MGIT broth samples.
Clinical characterization of serum SP-D and serum KL-6 levels in patients with drug-induced lung injury associated with lung cancer chemotherapy
<bold>Background:</bold> Drug-induced lung injury associated with lung cancer chemotherapy is a serious adverse event that can complicate treatment management and worsen prognosis. However, there are limited reports on the usefulness of serum SP-D and KL-6 in drug-induced lung injury related to lung cancer drug therapy. We aimed to investigate the clinical significance of serum SP-D and KL-6 in this condition. <bold>Method:</bold> We conducted a retrospective study of 121 patients who had serum SP-D and KL-6 measured at the time of diagnosis of drug-induced lung injury at our hospital and collaborating institutions. SP-D and KL-6 levels at disease onset were analyzed using descriptive statistics. We defined the differences between the values at onset and those at the initiation of lung cancer drug therapy as ⊿SP-D and ⊿KL-6, respectively. ROC analysis and multivariate analysis were performed to assess their association with disease severity, comparing CTCAE pneumonitis severity Grade 1–2 and Grade 3–5 groups. <bold>Results:</bold> In ROC analysis, the AUC for ⊿SP-D and ⊿KL-6 were 0.66 and 0.50, respectively. The optimal cutoff values were 108 for ⊿SP-D and 141 for ⊿KL-6. In multivariate analysis, the odds ratios of ⊿SP-D and ⊿KL-6 above the cutoff values were 3.8 and 0.9, respectively, with ⊿SP-D showing a statistically significant difference. <bold>Conclusion:</bold> SP-D and KL-6 may be useful biomarkers for diagnosing drug-induced lung injury and can be detected with high sensitivity when used in combination. We also report on its potentially important role in disease assessment, and severity prediction.
Read moreOccult desaturation predicts poor prognosis in interstitial lung disease
<bold>Background:</bold> Exertional desaturation is an important predictor of mortality in interstitial lung disease (ILD) and is generally defined as a decrease in SpO<sub>2</sub> to 88% or lower during the 6-minute walk test (6MWT). However, some patients exhibit a decline in SpO<sub>2</sub> of 4% or more while maintaining SpO<sub>2</sub> above 88%. This subtle oxygen decline, referred to as occult desaturation, may have prognostic significance. <bold>Objective:</bold> To investigate the prognostic significance of occult desaturation in patients with ILD. <bold>Methods:</bold> We retrospectively analyzed consecutive patients with ILD who underwent 6MWT. Patients were classified into three groups based on SpO<sub>2</sub> after the 6MWT: no desaturation group (decline <4% and >88%), occult desaturation group (decline ≥4% and >88%), desaturation group (≤88%). <bold>Results:</bold> A total of 1,283 patients were included (age 68.0 years, 34.8% female, FVC 84.0%, DL<sub>CO</sub> 64.2%). Patients were classified as follows: 239 in the no desaturation group, 340 in the occult desaturation group, and 704 in the desaturation group. Multivariable analysis showed that group classification was significantly associated with poor prognosis. Compared with the no desaturation group, the occult desaturation group had a significantly worse prognosis in the overall cohort. This association between the occult desaturation group and worse prognosis was also observed in patients with idiopathic pulmonary fibrosis (IPF), but not those with non-IPF ILD. <bold>Conclusions:</bold> Occult desaturation was associated with poor prognosis in patients with ILD, particularly in those with IPF. This finding suggests that even modest oxygen decline may indicate worse outcomes and should not be overlooked.
Read moreClinical outcomes, safety, and potential prognostic factors of noninvasive respiratory support in patients with COVID-19: A Japanese multicenter observational study.
National survey of Hutchinson-Gilford progeria syndrome and progeroid laminopathy in Japan
Background and Aim: Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (PL) are rare genetic disorders characterized by accelerated aging and early onset cardiovascular complications. Despite recent advances in the genetic diagnosis of HGPS and PL and the advent of lonafarnib treatment, the epidemiology and clinical characteristics of these disorders in Asia remain unclear. This study aimed to assess the prevalence, clinical features, and diagnostic trends of the HGPS and PL in Japan.Methods: A nationwide two-step survey was conducted between July 2022 and January 2024, across 1,513 medical facilities.Results: The survey identified ten HGPS patients, including eight with a confirmed genetic diagnosis. Early onset features such as scleroderma-like skin changes, growth retardation, and joint contracture were important in facilitating an early and accurate diagnosis. Cardiovascular complications typically occurred during their teens, and abnormalities in lipid metabolism were frequently observed. Overlapping but distinct phenotypes have been noted in ZMPSTE24 deficiency and other laminopathies caused by LMNA pathogenic variants, such as Emery-Dreifuss muscular dystrophy. Four patients with definite HGPS and eight patients with progerin-related PL (definite HGPS, n = 4; uncertain HGPS, n = 2; ZMPSTE24 deficiency, n = 2) were reported alive on October 2023, and the prevalence of HGPS was estimated to be 1 in 15.5 to 31.1 million.Conclusions: This study provides updated epidemiological and clinical insights into HGPS and related laminopathies in Japan. The introduction of lonafarnib has the potential to extend survival, emphasizing the need to monitor for late-stage complications.
Read moreFever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis
Introduction: Liver injury is a treatment-related adverse event (liver-TRAE), one of the most common complications of atezolizumab plus bevacizumab (Atez/Bev) therapy, when treating unresectable hepatocellular carcinoma (uHCC). Fever following immune checkpoint inhibitor (ICI) therapy may predict ICI-induced liver injury in various malignancy types. However, the association between fever and liver-TRAEs in patients with uHCC treated with Atez/Bev has not been investigated. We prospectively evaluated the relationship between the onset of liver-TRAEs and preceding fever and sought to identify circulating biomarkers that predict liver injury in patients with Atez/Bev-treated uHCC. Methods: The primary outcome of this prospective, multicenter study was the association between liver-TRAEs (grade ≥2) and the presence of ICI-induced fever before the onset of liver injury. We used a multiplex bead-based immunoassay to evaluate 40 circulating proteins in the serum before and at 1, 3, and 6 weeks after initial Atez/Bev treatment. Results: Among 99 patients receiving Atez/Bev, grade ≥2 liver-TRAEs occurred in 10 (10.1%) during the follow-up period (median, 14.7 months). The incidences of liver-TRAEs associated with fever before liver injury were 27.8% (n = 5/18) and 6.2% (n = 5/81) in the fever and non-fever groups, respectively. Multivariable analysis showed that the presence of fever was a significant risk factor for liver-TRAEs (odds ratio 7.57; 95% confidence interval, 1.83–33.89; p = 0.006). Furthermore, the prognosis was worse in the liver-TRAE (grade ≥2) group (p = 0.065 for progression-free survival and p = 0.074 for overall survival). Among patients with preceding fever, the liver-TRAE group had significantly lower CXCL-5 levels before treatment, higher IL-6 levels at 1 and 3 weeks, and lower CXCL-5, IFN-γ, and IL-10 levels at 6 weeks (p < 0.05). Conclusion: Fever during Atez/Bev treatment may predict liver-TRAEs, which leads to poor prognosis in patients with uHCC. Altered inflammatory cytokine and chemokine levels may help predict liver-TRAEs in patients with fever after Atez/Bev therapy.
Read moreABS0312 EFFICACY OF AVACOPAN AS INDUCTION THERAPY IN ANCA-ASSOCIATED VASCULITIS: A JAPANESE MULTICENTER COHORT STUDY (J-CANVAS STUDY)